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Tumor necrosis factor (TNF) caused inhibition of collagen production by confluent cultures of human dermal fibroblasts 
in a dose-dependent manner. Concomitant increase of prostaglandin E2 release was observed as a result of TNF-induced 
cell activation. However, a blockade of the cyclooxygenase pathway of arachidonate metabolism by indomethacin did 
not abrogate the inhibitory effect of TNF on collagen synthesis, suggesting that this effect could be independent of pros- 
taglandin metabolism. Gel electrophoresis of the newly synthesized macromolecules from the culture media showed that 
both type I and type III collagens as well as fibronectin were affected by the inhibition. Electrophoresis of cell layer- 
associated proteins demonstrated that the reduction in amounts of collagen and fibronectin in the medium did not result 
from an intracellular accumulation of these macromolecules. Production of procollagens was reduced in parallel to that 
of collagens, suggesting that the effect of TNF is exerted before the processing steps of procollagens. These results clearly 
show that TNF could play a role in modulation of matrix deposition by fibroblasts during inflammatory processes. 
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1. INTRODUCTION 
Tumor necrosis factor, cachectin, is a 17 kDa 
polypeptide released by macrophages and 
monocytic cell lines stimulated with bacterial en- 
dotoxin [l] playing a crucial role in inflammatory 
response and tumor lysis. Besides cytotoxic and 
cytostatic activities on mice and human tumor cell 
lines [2,3], TNF induces multiple responses in 
several cell types, including connective tissue cells. 
For example, TNF has been shown to stimulate 
both prostaglandin E2 (PGEz) and collagenase 
release in cultured synovial cells [4]. It also 
enhances resorption of proteoglycans and inhibits 
their synthesis in cartilage explants [5]. In contrast 
to its cytostatic effect on tumor cells, TNF exerts 
growth-stimulating action on normal human 
fibroblasts [6]. 
Thus, in several cases, TNF shares many 
biological activities with interleukin-1 (IL-l) [7-91. 
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The role of this latter cytokine as a potent 
stimulant of extracellular matrix degradation and 
its implication in both inflammatory and 
degenerative joint diseases have been well 
documented (review in [lo]). We and other authors 
have also reported that IL-l could modulate the 
production of collagen in cultured fibroblasts 
[11,12], synovial cells [13-151 and articular chon- 
drocytes [14,16]. Since TNF has been demonstrat- 
ed as a mediator of inflammation [17], it was of 
interest to determine whether this monokine could 
also act on the production of extracellular matrix 
proteins as does IL-l. Attempting to address this 
hypothesis, we report here that recombinant TNF 
can inhibit in vitro the synthesis of collagen and 
fibronectin by dermal fibroblasts. We also provide 
evidence that this effect is not due to stimulation of 
prostaglandin formation. 
2. MATERIALS AND METHODS 
2. I. Fibroblast culture 
Human dermal fibroblasts obtained by explants from 
foreskin samples, were cultured in Dulbecco’s modification of 
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Eagle’s minimum essential medium (DMEM) supplemented 
with 10% heat inactivated fetal calf serum (FCS), penicillin 
(100 IU/ml), streptomycin (100 pg/ml) and fungizone 
(2.5 pg/ml). The cells were grown at 37’C in a 5% CO2 at- 
mosphere and experiments were performed on confluent 
cultures to minimize the growth-stimulating effect of TNF. 
2.2. TNF preparation 
Throughout this study we used recombinant human TNF-cu, 
produced by E. coli and purified to homogeneity by BASF, 
FRG. 
2.3. Experimental procedure 
For the experiments, cells were grown in 9.6 cm2 dishes. 
After reaching confluency, the cultures were preincubated for 
24 h in DMEM supplemented with 2% FCS and SOpg/ml 
ascorbic acid (Sigma). Then the media were removed and fresh 
medium containing also 50 pg/ml,&aminopropionitrile (Sigma) 
was added, with or without TNF. After a 24 h incubation, the 
media were collected and used to assay PGEz content whereas 
the cell layers were washed twice with phosphate-buffered saline 
(PBS) and dissolved in 0.2 M NaOH for subsequent protein 
determination. Estimation of total collagen production was per- 
formed under the same conditions, in the presence of 2 &i/ml 
[3H]proline (CEA, France, 30-40 Ci/mmol). For determina- 
tion of the amounts of type I and III collagens and fibronectin 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
radiolabelling was performed with 25 &i/ml [3H]proline in 
25 cm” flasks. 
2.4. Assay of labelled collagen and non-collagenous proteins 
In the experimental conditions used, more than 95% of the 
newly synthesized collagen was recovered in the culture 
medium. Therefore, only collagen from the medium was 
assayed, as collagenase-digestible protein [18], using purified 
enzyme from Advance Biofactures Corp., Lynnbrook, NY. 
Results were expressed as dpm/pg of cell protein. The amount 
of non-collagenous protein was estimated from the radioactivi- 
ty remaining after collagenase digestion. Proportion of collagen 
among other radioactive proteins was calculated with the 
following formula that takes into account the enrichment of 
proline in collagen compared with other proteins [19]: 
% of collagen = 
dpm in collagenase digest x 100 
(5.4 x dpm in residue) + dpm in collagenase digest) 
2.5. Analysis of radiolabelled proteins by gel electrophoresis 
At the end of experiments, the media were collected and one 
half of each sample received proteinase inhibitors to final con- 
centrations of 20 mM EDTA, 10 mM N-ethylmaleimide and 
1 mM phenylmethylsulfonyl fluoride. Both fractions were 
dialyzed against 1 mM ammonium carbonate buffer (pH 7.5) 
and lyophilized. The sample half without inhibitors was then 
digested with pepsin (0.1 mg/ml, Sigma, 2 x tryst.) in solution 
containing L-proline (400 pg/ml) and acetic acid (0.5 M) at 4°C 
for 15 h. After lyophilization, the samples were run through a 
6% polyacrylamide gel containing SDS and 2 M urea as 
described by O’Farrell [20]. The cell layers were directly lysed 
in O’Farrell’s sample buffer and the extracts analyzed in the 
same way. The samples were reduced or not by p- 
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mercaptoethanol (0.1 M). After electrophoresis, the gels were 
fixed and prepared for fluorography as described previously 
[21]. The amount of radioactivity present in the bands cor- 
responding to fibronectin and collagen chains was estimated by 
densitometry. 
2.6. Prostaglandin EZ assay 
PGE2 was assayed in the culture medium by specific radioim- 
munoassay [22] with antiserum from Institut Pasteur Produc- 
tion, Marnes la Coquette, France. 
2.7. Cell protein determination 
After dissolution of cell layer with 0.2 M NaOH, the amount 
of protein was assayed by the method of Hartree [23], using 
albumin as a standard. 
2.8. Statistical analysis 
All the results presented are expressed as mean + SE unless 
stated otherwise. The Student’s t-test was used to evaluate the 
difference of the means between groups. 
3. RESULTS 
3.1. TNF inhibition of collagen and non- 
collagenous protein synthesis 
There were no obvious differences in cell mor- 
phology under the phase contrast microscope be- 
tween control and TNF-treated cultures. Fibro- 
blasts were exposed to three concentrations of 
TNF for 24 h: 1, 10 and 100 ng/ml. As little as 
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Fig. 1. Effect of TNF on collagen and non-collagenous protein 
synthesis. Confluent fibroblasts were incubated for 24 h in the 
presence of varying concentrations of TNF and [3H]proIine as 
described in section 2. Amounts of radiolabelled collagen and 
non-collagenous protein are expressed in dpm/pg of cell layer 
protein and represented as a percentage of controls (values for 
controls: collagen, 184 + 12 dpm/Fg cell protein; non- 
collagenous protein, 279 t 14 dpm/pg cell protein). The results 
are means + SE of triplicate dishes. * p < 0.01, ** p < 0.001. 
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lagen and non-collagenous protein production by 
30 and 23%, respectively (fig. 1). Maximum inhibi- 
tion of collagen synthesis was observed for 
10 ng/ml (60%) and reached a plateau. The pro- 
duction of non-collagen was less affected since on- 
ly 30% inhibition was registered for the highest 
concentration of TNF used, 100 ng/ml. The 
relative proportion of collagen among the total 
newly synthesized protein, taking into account the 
enriched imino acid content of collagen, was 
therefore reduced from 11.2% in control cultures 
to 10.0, 6.1 and 6.7% in the cultures exposed to 1, 
10 and 100 ng/ml TNF, respectively. 
Despite fibroblasts being used after reaching 
confluency, a growth-enhancing action of TNF 
was observed for concentrations of 10 and 
100 ng/ml, whereas 1 ng/ml was without signifi- 
cant effect. Increases of cell proliferation, 
measured in terms of cell protein, reached 16 and 
24% above controls for 10 and 100 ng/ml TNF, 
respectively (p < 0.05, n = 3). 
3.2. Effect of TNF on the production of PGE2 by 
fibroblasts 
To investigate further the mechanism of 
fibroblast activation by TNF and to what extent 
the inhibitory effect on collagen synthesis could be 
related to arachidonate metabolism, we assayed 
the level of PGE2 in the culture medium in parallel 
to collagen labelling. Results shown in table 1 
clearly demonstrate that TNF markedly stimulated 
the secretion of PGE2 by dermal fibroblasts in a 
dose-dependent manner. Enhancement reached 4.5 
to 12.8-fold the values of control cultures when 
TNF concentrations varied from 1 to 100 ng/ml. 
Table 1 
PGE2 production by dermal fibroblasts treated with TNF 
Sample Prostaglandin E2 
pg/ml % of control 
Control 658 + 127 100 
TNF, 1 ng/ml 2968 + 94” 451 
TNF, 10 ng/ml 4673 f 14Y 710 
TNF, 100 ng/ml 8416 + 774a 1279 
Experimental conditions were the same as for fig. 1. Results are 
means + SE of triplicate dishes. a p < 0.001 
3.3. Addition of indomethacin does not abolish 
the TNF-induced inhibition of collagen 
synthesis 
Given that the depression of collagen synthesis 
induced by TNF occurred concomitantly to a huge 
increase of PGE2 released in the medium, and that 
PGE2 has been reported to inhibit collagen syn- 
thesis [23], it was of interest to determine whether 
addition of a blocker of the cyclooxygenase 
pathway of arachidonate metabolism could 
modify the outcome. The results shown in fig.2 in- 
dicate that addition of indomethacin (Indo) did 
not abrogate the inhibitory effect of TNF on col- 
lagen synthesis, the difference between the value 
for ‘TNF + Indo’ compared to that of ‘Indo’ re- 
maining statistically significant. These data suggest 
that TNF exerts its effect on collagen production 
through mechanisms that seem unrelated to 
prostaglandin metabolism. 
3.4. SDS-PAGE analysis of radiolabelled 
collagens and fibronectin 
To investigate further the effect of TNF on 
matrix deposition, newly synthesized proteins 
from the media of cultures treated with increasing 
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Fig.2. Effect of indomethacin (10pM) on the inhibition of 
collagen synthesis by TNF (10 ng/ml). Experimental conditions 
were the same as for fig. 1. Results, expressed in dpm/pg of cell 
protein, are means + SE of triplicate dishes. * p < 0.01, ** p < 
0.001. 
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Fig.3. SDS-PAGE fluorograph of medium proteins. (A) Total 
proteins after reduction with ,L?-mercaptoethanol (0.1 M). FN, 
fibronectin; procoll., procollagens. (B) Pepsin-digested proteins 
without reduction. Collagen chains are indicated by 
arrowheads. 
PAGE and subsequent fluorography, with and 
without pepsin digestion. The fluorograms are 
shown in fig.3A and B and the scannings of pro- 
collagen, collagen and fibronectin bands are 
presented in table 2 as arbitrary densitometric 
units. These results confirm the inhibitory effect of 
TNF on collagen synthesis and show that both type 
I and type III were affected. The proportion of 
type III collagen produced by our cultures was 
small, so that we could not quantify it as 
dissociated crr(II1) chains after interrupted elec- 
trophoresis (not shown). The band corresponding 
to the trimeric form [cui(III)]3 (fig.3A) was too 
faint to really determine the amount of type III 




ng/ml 10 ng/ml ng/ml 
Fibronectin 
(100) 
+ c?(I) 4116 4161 
(100) (101) (59) (44) 
lW(W13 255 117 
(100) (46) (l?) 
Procollagens 2820 2671 
(100) (95) (87) 
Results units and qo of 
respective controls are indicated 
from these experiments whether 
tion extent is the for collagens not. 
Fibronectin production was decreased 
seen in fig.3A. 
that the reduc- 
tion 
media did not result from these 
proteins cell layer since no increase 
could be observed 
bands (fluorographs More- 
over, 
were reduced 
same extent as in culture 
Many similarities have been shown between the 
activities IL-l, two major monocyte- 
macrophage-derived 
Both exert broad effects 
cells connective tissue. Their ability 
been 
documented their implication therefore sug- 
gested 
tive effects IL-l exerted through stimulation 
[8], a modulating 
this cytokine 
also demonstrated [ 1 Concerning 
collagen we have shown 
that could augment steady-state level 
procollagen I III mRNAs human synovial 
[15] and fibroblasts [26]. in 
spite this increase mRNA level, reduction of 
amount of released into culture 
medium very often suggesting that 
events can the pro- 
of collagen IL-l-treated cells, least in 
vitro systems In the paper, 
we that recombinant is capable 
inhibiting collagen fibronectin synthesis 
human dermal Interestingly, a 
effect of has been observed on 
lagen synthesis fetal rat cultures [27]. 
results suggest TNF displays same 
modulating as IL-l collagen produc- 
by connective cells. 
The observed here the radioactivity 
in collagen fibroblasts exposed 
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TNF could be due to decreased collagen synthesis, 
increased collagen degradation or both. It is dif- 
ficult to rule out an eventual degradation of the 
collagen after secretion in the medium since TNF, 
like IL-l, was shown to stimulate collagenase 
release by synovial cells and fibroblasts [4]. 
However, we believe that it is unlikely that this 
process could account for the reduction of collagen 
recovered from the medium since collagenase is 
produced as an inactive form. Moreover, our 
cultures contain serum that would block any col- 
lagenase activity if present. For example, we have 
never found any spontaneously active collagenase 
in our earlier studies with IL-l, using the same ex- 
perimental conditions [28]. Enhanced intracellular 
degradation of newly synthesized collagen mole- 
cules has also been suggested to play a role in the 
reduction of collagen production under the in- 
fluence of IL-l [ 14,151. This hypothesis is based on 
the fact that activation of target cells by cytokines 
such as IL-l and TNF generally provokes a rise in 
the concentration of intracellular CAMP, a 
messenger which has been reported to stimulate the 
degradation of newly synthesized collagen [29,30]. 
However, this remains to be confirmed on an ex- 
perimental basis. It is more likely that the reduc- 
tion of collagen caused by TNF was predominantly 
due to decreased synthesis. We do not know yet 
what the mechanism is by which TNF exerts this 
inhibitory effect. Work is in progress to determine 
whether procollagen mRNA level is altered by the 
factor and to what extent there is a similarity with 
the mode of action of IL-l. Previous reports have 
shown that the inhibition of collagen synthesis in- 
duced by IL-l may be related in part to prostaglan- 
din generation since addition of indomethacin 
frequently reversed the effect and produced an in- 
crease of collagen synthesis [13,14]. In support of 
this interpretation, it should be noted that ex- 
ogenous PGEz added to cultures of fibroblasts 
causes a decrease in the level of procollagen 
mRNA [24] whereas indomethacin acts in the op- 
posite way [31]. TNF has been reported to activate 
phospholipase A2 in osteoblasts, synovial cells and 
fibroblasts [32] and the consequent formation of 
PGE2. This was confirmed in the present studies 
since a great increase in PGE;! release was ob- 
served. However, our results are not consistent 
with a role of PGE2 in TNF action on collagen syn- 
thesis as no change was noticed in the presence of 
indomethacin, a cyclooxygenase inhibitor. Further 
research is needed to clarify the mechanism of 
TNF effects on collagen synthesis. 
Recently, it has been demonstrated that 
fibroblasts can produce cytokines when stimulated 
with immunomodulators such as lipopolysac- 
charide or phorbol myristate acetate [33] or with 
cytokines themselves [34]. Therefore, it cannot be 
excluded that the effects observed in our ex- 
periments could be partly due to cytokines secreted 
by the fibroblasts as a result of TNF stimulation. 
For example, IL-l or TNF-stimulated fibroblasts 
produce interferon& (IFN-,&), a cytokine with 
antiviral properties [35]. However, we have recent- 
ly shown that purified IFN-fl2 was without effect 
on both collagen and PGE2 formation by 
fibroblasts (unpublished). Nevertheless, we do not 
know whether IL-l or IFN-7 could be expressed by 
TNF-activated fibroblasts and act as an amplifica- 
tion loop on the collagen synthesis. 
In conclusion, we have shown that TNF is one 
factor responsible for inhibition of collagen syn- 
thesis that may play a role in the modulation of 
matrix turnover during inflammatory diseases. 
ADDENDUM 
While this manuscript was being submitted, a 
paper was published on the same subject by Solis- 
Herruzo et al. [36]. Our study is in accordance with 
their data and extends them further to fibronectin. 
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